Effects of multidisciplinary therapy on physical function in Huntington's disease.

Cruickshank TM, Reyes AP, Penailillo LE, Pulverenti T, Bartlett DM, Zaenker P, Blazevich AJ, Newton RU, Thompson JA, Lo J, Ziman MR.

Acta Neurol Scand. 2018 Jul 30. doi: 10.1111/ane.13002. [Epub ahead of print]

Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease.

Gouarné C, Tardif G, Tracz J, Latyszenok V, Michaud M, Clemens LE, Yu-Taeger L, Nguyen HP, Bordet T, Pruss RM.

PLoS One. 2013 Nov 26;8(11):e81528. doi: 10.1371/journal.pone.0081528.

Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.

Ribeiro FM, Devries RA, Hamilton A, Guimaraes IM, Cregan SP, Pires RG, Ferguson SS.

Hum Mol Genet. 2014 Apr 15;23(8):2030-42. doi: 10.1093/hmg/ddt598.

Huntington’s Disease: Clinical Experimental Therapeutics.

E. Ray D, Ira S.

In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 12.

The personal experience of parenting a child with juvenile Huntington's disease: perceptions across Europe.

Eatough V, Santini H, Eiser C, Goller ML, Krysa W, de Nicola ', Paduanello M, Petrollini M, Rakowicz M, Squitieri F, Tibben A, Weille KL, Landwehrmeyer B, Quarrell O, Smith JA.

Eur J Hum Genet. 2013 Oct;21(10):1042-8. doi: 10.1038/ejhg.2013.15.

hMTH1 expression protects mitochondria from Huntington's disease-like impairment.

Ventura I, Russo MT, De Nuccio C, De Luca G, Degan P, Bernardo A, Visentin S, Minghetti L, Bignami M.

Neurobiol Dis. 2013 Jan;49:148-58. doi: 10.1016/j.nbd.2012.09.002.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators.; REGISTRY investigators., Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.

The Prevalence of Huntington's Disease.

Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ, Smeeth L.

Neuroepidemiology. 2016;46(2):144-53. doi: 10.1159/000443738. Review.

AUTEN-67 (Autophagy Enhancer-67) Hampers the Progression of Neurodegenerative Symptoms in a Drosophila model of Huntington's Disease.

Billes V, Kovács T, Hotzi B, Manzéger A, Tagscherer K, Komlós M, Tarnóci A, Pádár Z, Erdős A, Bjelik A, Legradi A, Gulya K, Gulyás B, Vellai T.

J Huntingtons Dis. 2016 May 7;5(2):133-47. doi: 10.3233/JHD-150180.

The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Munoz-Sanjuan I, Bates GP.

J Clin Invest. 2011 Feb;121(2):476-83. doi: 10.1172/JCI45364. Review.

Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism.

Chen JY, Tran C, Hwang L, Deng G, Jung ME, Faull KF, Levine MS, Cepeda C.

J Huntingtons Dis. 2016;5(1):65-81. doi: 10.3233/JHD-150181.

T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression.

Wassef SN, Wemmie J, Johnson CP, Johnson H, Paulsen JS, Long JD, Magnotta VA.

Mov Disord. 2015 Jul;30(8):1107-14. doi: 10.1002/mds.26203.

Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice.

Im W, Lee ST, Park JE, Oh HJ, Shim J, Lim J, Chu K, Kim M.

PLoS Curr. 2010 Sep 26;2. pii: RRN1183. doi: 10.1371/currents.RRN1183.

Substance abuse may hasten motor onset of Huntington disease: Evaluating the Enroll-HD database.

Schultz JL, Kamholz JA, Moser DJ, Feely SM, Paulsen JS, Nopoulos PC.

Neurology. 2017 Feb 28;88(9):909-915. doi: 10.1212/WNL.0000000000003661.

Brain training improves cognitive performance and survival in a transgenic mouse model of Huntington's disease."

Wood NI, Glynn D, Morton AJ.

Neurobiol Dis. 2011 Jun;42(3):427-37. doi: 10.1016/j.nbd.2011.02.005.